Doctor Nicole van der Weerden completed her PhD in Biochemistry at La Trobe University in 2007. Her PhD research on the antifungal properties and mechanism of action of plant defensins led to the award of a prestigious Victoria Fellowship in 2006. Since completing her PhD, Nicole has worked for Hexima Limited and has led the discovery and development program for novel peptide therapeutics for fungal infections. Hexima’s lead product, HXP124, has recently completed phase I/IIa clinical trials in Australia with very promising results. Nicole completed an MBA in 2013 at Melbourne Business School and was appointed Hexima’s Chief Executive Officer in December 2015.